Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer

被引:77
|
作者
De Jaeger, K
Seppenwoolde, Y
Boersma, LJ
Muller, SH
Baas, P
Belderbos, JSA
Lebesque, JV
机构
[1] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands
[2] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Antoni van Leeuvenhoek Hosp, Dept Chest Oncol, NL-1066 CX Amsterdam, Netherlands
关键词
pulmonary function; SPECT; perfusion; tumor response; mean lung dose;
D O I
10.1016/S0360-3016(02)04389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To study changes of pulmonary function tests (PFTs) after radiotherapy (RT) of non-small-cell lung cancer (NSCLC) in relation to radiation dose, tumor regression, and changes in lung perfusion. Methods and Materials: Eighty-two patients with inoperable NSCLC were evaluated with PFTs (forced expiratory volume in 1 s [FEVt] and diffusion capacity [T-L,T-COc]), a computed tomography (CT) scan of the chest, and a single photon emission CT (SPECT) lung perfusion scan, before and 3-4 months after RT. The reductions of PFTs and tumor volume were calculated. The lung perfusion was measured from pre- and post-RT SPECT scans, and the difference was defined as the measured perfusion reduction (MPR). In addition, the perfusion post-RT was estimated from the dose distribution using a dose-effect relation for regional lung perfusion, and compared with the pre-RT lung perfusion to obtain the predicted perfusion reduction (PPR). The difference between the actually measured and the PPR was defined as reperfusion. The mean lung dose (MLD) was computed and weighted with the pre-RT perfusion, resulting in the mean perfusion-weighted lung dose (MpLD). Changes of PFTs were evaluated in relation to tumor dose, MLD, MpLD, tumor regression, and parameters related to perfusion changes. Results: In a multivariate analysis, the total tumor dose and MLD were not associated with reductions of PFTs. Tumor regression resulted in a significant improvement of FEV1 (p = 0.02), but was associated with a reduction of T-L,T-COc. (P = 0.05). The MpLD and the PPR showed a significant (p = 0.01 to 0.04) but low correlation (r = 0.24 to 0.31) with the reduction of both PFTs. The other parameters for perfusion changes, the MPR and reperfusion were not correlated with changes in PFTs. Conclusion: The perfusion-related dose variables, the MpLD or the PPR, are the best parameters to estimate PFTs after RT. Tumor regression is associated with an improvement of FEV1 and a decline of T-L,T-COc. Reperfusion was not associated with an improvement of global pulmonary function. (C) 2003 Elsevier Science Inc.
引用
收藏
页码:1331 / 1340
页数:10
相关论文
共 50 条
  • [41] RADIOTHERAPY IN THE MANAGEMENT OF NON-SMALL-CELL LUNG-CANCER
    BEZJAK, A
    PAYNE, D
    WORLD JOURNAL OF SURGERY, 1993, 17 (06) : 741 - 750
  • [42] High-dose radiotherapy in patients with stage III non-small cell lung cancer in practical experience
    Nakayama, H.
    Tokuuye, K.
    Ishikawa, H.
    Kurishima, K.
    Kanamoto, K.
    Kikuchi, S.
    Ichimura, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S522 - S523
  • [43] Feasibility Study on the Central of Massive Lesion in Non-Small Cell Lung Cancer with High-Dose Radiotherapy
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1089 - S1089
  • [44] Stereotactic body radiotherapy for early stage non-small-cell lung cancer in patients with very poor pulmonary function
    Henderson, M. A.
    McGarry, R. C.
    Yiannoutsos, C.
    Timmerman, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S91 - S91
  • [45] Dose, volume, and tumor control predictions in primary radiotherapy of non-small-cell lung cancer
    Willner, J
    Baier, K
    Caragiani, E
    Tschammler, A
    Flentje, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (02): : 382 - 389
  • [46] High-dose chemotherapy in small cell lung cancer
    Pasini, F
    Pelosi, G
    De Manzoni, G
    Rosti, G
    TUMORI, 2002, 88 (03) : 179 - 186
  • [47] DOSE-VOLUME COMPARISON OF PROTON RADIOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER
    Kadoya, Noriyuki
    Obata, Yasunori
    Kato, Takahiro
    Kagiya, Masaru
    Nakamura, Tatsuya
    Tomoda, Takuya
    Takada, Akinori
    Takayama, Kanako
    Fuwa, Nobukazu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1225 - 1231
  • [48] Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
    Chin, Alexander L.
    Kumar, Kiran A.
    Guo, Haiwei H.
    Maxim, Peter G.
    Wakelee, Heather
    Neal, Joel W.
    Diehn, Maximillian
    Loo, Billy W., Jr.
    Gensheimer, Michael F.
    CLINICAL LUNG CANCER, 2018, 19 (05) : E581 - E588
  • [49] Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer
    Grambozov, Brane
    Wolf, Frank
    Kaiser, Julia
    Wass, Romana
    Fastner, Gerd
    Gaisberger, Christoph
    Rettenbacher, Lukas
    Studnicka, Michael
    Pirich, Christian
    Sedlmayer, Felix
    Zehentmayr, Franz
    THORACIC CANCER, 2020, 11 (02) : 369 - 378
  • [50] Autotransplantation for central non-small-cell lung cancer - in a patient with poor pulmonary function
    Reardon, MJ
    Walkes, JCM
    Rice, DC
    TEXAS HEART INSTITUTE JOURNAL, 2004, 31 (04) : 360 - 362